SecBot SecBot
Biotech Drug Report Generated Nov 5, 2026

SPY120

SYRE·Spyre Therapeutics, Inc.
MIXED
Drug Impact Rating6/10
Trial phase
Phase 2
Time to market
SPY120 is in Phase 2 with Part B induction data expected in 2027. If successful, Phase 3 trials would follow, meaning potential approval is likely several years away (late 2029 or later under an optimistic scenario).
Why 6/10
The next hard catalyst for SPY120 is the SKYLINE Part B induction topline readout, expected in 2027 (likely Q3 2027 per the company's Q3 2026 earnings report). This is a dated binary event within roughly 10 months on a program that is a major value driver for Spyre, though the company also has other pipeline programs (SPY072 for hidradenitis suppurativa, SPY772) and a ~$10.3B market cap, so the score is 6 rather than higher.
Actionable Insight MIXED

The next major catalyst for SPY120 is the SKYLINE Part B induction readout expected in 2027. Positive data showing the SPY001+SPY002 combination outperforms either monotherapy would validate Spyre's combination strategy and likely drive the stock toward the $122.53 analyst mean target. Negative or equivocal data would raise serious doubts about the rationale for combining these mechanisms and could trigger significant downside given the stock's elevated short volume and the $10.3B market cap that already prices in substantial pipeline optimism.

Price Chart

Loading chart...

Executive Summary

SPY120 is a Phase 2 combination antibody therapy from Spyre Therapeutics (NASDAQ: SYRE) for ulcerative colitis, pairing an anti-alpha4beta7 antibody (SPY001) with an anti-TL1A antibody (SPY002). All three monotherapy components have achieved proof-of-concept in the SKYLINE trial's Part A. The combination arms (SPY120, SPY130, SPY230) are now enrolling in Part B with induction data expected in 2027. Spyre has a strong cash position of $1.5B (pro forma) funding operations into 2H 2029, broad institutional support (Fidelity, BlackRock, RTW as top holders), and a bullish analyst consensus (21 buy/strong-buy vs 2 hold, mean price target $122.53). However, the stock faces headwinds: a recent $350M dilutive offering at $85/share, elevated short volume, insider selling under 10b5-1 plans, and the failure of sister-program SPY072 in rheumatoid arthritis/axSpA. SPY120's combination data in 2027 is the key binary catalyst for the stock.

How It Works

SPY120 is a fixed-dose combination of two lab-made antibodies given as a single injection. One antibody (SPY001) blocks alpha4beta7, a protein on immune cells that helps them travel to the gut; the other (SPY002) blocks TL1A, a signaling protein that drives inflammation. By hitting both targets at once, the drug aims to stop immune cells from reaching the gut and also turn down the inflammatory signal, potentially offering better control of inflammatory bowel disease than either approach alone.

Trial Status

SPY120 is being tested in the Phase 2 SKYLINE platform trial (NCT07012395) for moderately-to-severely active ulcerative colitis. Part A of SKYLINE has completed and demonstrated proof-of-concept for all three monotherapy components (SPY001, SPY002, SPY003), with the last positive readout reported on September 8, 2026 for SPY003. Part B is actively enrolling and includes SPY120 (SPY001 + SPY002), SPY130 (SPY001 + SPY003), and SPY230 (SPY002 + SPY003) combination arms at high doses, using a factorial design to compare combinations against monotherapies and placebo.

The Two-Sided Case

▲ Bull Case5
All three monotherapy components (SPY001, SPY002, SPY003) achieved proof-of-concept in SKYLINE Part A, with SPY003 described by management as 'potential best-in-class' (Sept 8, 2026 press release).
Preclinical data showed that combined alpha4beta7 and TL1A inhibition produced superior efficacy versus either monotherapy alone, providing a strong rationale for the SPY120 combination.
The YTE half-life extension technology could enable quarterly or twice-annual subcutaneous dosing, a major convenience advantage over current IBD therapies that require more frequent dosing.
Spyre has a deep cash runway of $1.5B (pro forma) into 2H 2029, removing near-term financing risk, and strong institutional ownership led by Fidelity ($1.16B position as of Q2 2026).
Analyst consensus is strongly bullish: 21 buy/strong-buy ratings, 2 hold, 0 sell, with a mean price target of $122.53 (23.4% upside from $99.27) per the November 2026 snapshot.
▼ Bear Case5
SPY120 is still in Phase 2 with no approved products or revenue; the SKYLINE Part B combination data (expected 2027) is a high-risk binary event that could fail to show superiority over monotherapies.
Spyre completed a dilutive $350M stock offering at $85/share in October 2026, increasing share count by ~4.1M shares (plus an underwriter option for another 0.6M).
Elevated short volume (64.2% of recent sessions' off-exchange volume vs a baseline of 58.1%, z-score 1.72) and insider selling under 10b5-1 plans signal bearish sentiment.
Sister program SPY072 failed primary endpoints in psoriatic arthritis and axial spondyloarthritis, raising questions about the breadth of the TL1A mechanism beyond IBD.
Competition is intensifying: MSD's tulisokibart (anti-TL1A) already has positive Phase 3 data in UC, and other anti-TL1A antibodies (afimkibart, duvakitug) have completed Phase 2 trials.

Upcoming Catalysts

  • SKYLINE Part B induction topline data for SPY120, SPY130, and SPY230 combinations expected in 2027 (likely Q3 2027 per company guidance).
  • SKYLIGHT Phase 2 trial of SPY072 in hidradenitis suppurativa with topline data expected late 2027 or early 2028.
  • Potential additional clinical data presentations at medical congresses (ECCO, UEG Week, DDW).

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Spyre Therapeutics, Inc. PRESS-RELEASE SYRE ·Originating report

Sources · 12

Hover a chip for the title
1 spyre.com2 synapse.patsnap.com3 clinicaltrials.gov4 biospace.com5 biospace.com6 ir.spyre.com7 adisinsight.springer.com8 academic.oup.com9 sec.gov10 sec.gov11 ir.spyre.com12 pharmaphorum.com